Fatal Side Effects

Home

30 days skin tansformation with tretinoin | How to use tretinoin without side effects/purging Side Effects 4 Views • 5 months ago

Hey lovies, alot of you has been asking me many questions about tretinoin and in this cideo i have covered all the points so Let’s talk about tretinoin. It is the hero ingredient that made my skin go from full of acne to clear glass skin in 30 days..Same lighting same angle, same location, same everything for the before and after photos ( i hsve shown in the video) just 30 days of difference. I am not lying .. this one product can give you tons of benefits, it can remove acne,acne scars. Wrinkles, fine lines age spot, pigmentation and it can lighten your skin with the price tag of just Rs:160 but if you don’t use it properly then this 1 product can give your skin tone of problems aswell.

So let’s understand how tretinoin works. In simple words. Tretinoin increases the cell turn over that means it replaces older skin with new skin by peeling off the outer most layer.

So now think if the outer most layer of the skin keep changing to new fresh one then how long will it take for your acne scars, pigmentation or wrinkles to vanish? Not long enough

But there’s a think which makes people leave tretinoin.. I call those people impatient and sensitive. let me explain in simple words tretinoin is a strong acid which works by increasing the cell turn over right? So when tretinoin is first introduced to our skin.. our skin don’t adjust with it and starts producing side effects such as dryness, redness, ichiness, acne breakouts which is totally normal..you have to understand that this is the process of Tretinoin working.. you will have to give your skin time to adjust with the newly introduced powerful ingredient tretinoin.. it will take around 1 or max 2 weeks for your skin to adjust with tretinoin and then tretinoin will start showing it’s magic. Avoid applying tretinoin near your eyes, mouth and nostril as they are sensitive places

Now even tho 2 weeks are not too long but it’s still hard to bear inching and dry skin for that long period.. so here’s how you can avoid getting side effects of Tretinoin.

The solution is Use hyaluronic acid with tretinoin. Make your skin damp and apply hyaluronic acid.. give it few minutes to absorb then take pea size amount of Tretinoin.. and apply it all over your face. Hyaluronic acid will maintain the skin barrier by giving it intense amount of hydration hence your skin won’t become dry, red or ichy.

Now there are many people who Complains that they are not getting any results after using tretinoin instead there skin is getting darker..

So there are 2 things that are very very very important if you are using tretinoin. They are moisturizer and sunscreen. As i said earlier tretinoin dries out the skin so you will need a good moisturizer, which has either ceramide, hyaluronic acid or vitamin E.

And while using tretinoin or any other acid based ingredients, sun becomes your worst enemy.. tretinoin or any active acid makes your skin sensitive to sunlight so if you go out in direct sunlight without any protection then your skin will get tanned and pigmented..so using a sunscreen is very important. Choose a sunscreen which has SPF50 with PA++++ rating and reapply every 4 hours if you are outdoor.

Now there are few people who are not supposed to use tretinoin. Lactating or pregnant women, people sensitive skin type and people who spends most of the time under sunlight.

For Sensitive skin type people you can use Retinol instead.

Now a lot of people ask me will they get the same results I got in 30 days of using tret? I would say maybe yes maybe not. Here me our first before coming at me.. one of my cousin had mild acne so her skin recovered in 2 weeks on the other hand one of my follower had acne acne scars for 6 years and she used my skincare routine and got 80% of her skin recovered in 4 months.. so the point to be noted here is.. you will get the results.. be it less than 30days or more than 30 days you will definitely get great results and after all that’s the goal right? To have fabulously clear skin.

Now lets talk about concentration. We mainly have 0.025% and 0.05% concentration of Tretinoin. You should always always always go for 0.025% one as a beginner. If you think higher concentration will give you faster results then that’s a no.. it will just give you too much side effects.

Now lets think about the long run. Tretinoin is great for anti aging right so if you are a person who wants to have glass like skin without any wrinkles at your 40 or 50s then start using tretinoin now. Start with applying tretinoin everyday for 1 year then use it on alternative days for 1 year. After that introduce 0.05% concentration of Tretinoin to your skin.. that time will be again a little painful for your skin. Once you are adjusted with 0.05%, use it 3 or 4 times a week for the rest of your life.. along with moisturizer and sunscreen.

Follow my social media

Instagram: https://instagram.com/thesristydutta
Facebook: https://www.facebook.com/sristy.dutta.54

How to Apply Tretinoin Cream I Tretinoin Journey I Tretinoin Side Effects Side Effects 0 Views • 5 months ago

Tretinoin is a topical medication commonly used to treat acne, reduce the appearance of fine lines and wrinkles, and improve the overall texture and tone of the skin. It is a form of retinoid, which is derived from vitamin A. Tretinoin should be used with care and under the guidance of a healthcare provider or dermatologist, as it can be potent and may cause skin irritation. Here are some general guidelines on how to use tretinoin:
check all products: https://bit.ly/4bUG7Tb
Consult a Healthcare Provider: Before starting tretinoin, consult with a dermatologist or healthcare provider to determine if it's the right treatment for your skin concerns. They will provide specific instructions based on your skin type and condition.

Start with a Low Concentration: Tretinoin comes in various concentrations, typically ranging from 0.025% to 0.1%. Beginners should start with a lower concentration to minimize the risk of irritation. Your healthcare provider will recommend the appropriate strength for your skin.

Apply at Night: Tretinoin is usually applied at night because it can make your skin more sensitive to sunlight. It's important to use a broad-spectrum sunscreen during the day to protect your skin from UV damage.

Cleanse Your Face: Before applying tretinoin, cleanse your face with a mild, non-alcoholic cleanser. Pat your skin dry with a clean towel.

Apply a Pea-Sized Amount: Use a small amount of tretinoin, about the size of a pea, to cover your entire face. Avoid applying it too close to your eyes, nostrils, and mouth.

Avoid Sensitive Areas: Be cautious around sensitive areas, such as the corners of your eyes and the corners of your mouth. Applying tretinoin to these areas can increase the risk of irritation.

Wait for Your Skin to Dry: Allow your skin to dry completely after cleansing before applying tretinoin. This helps reduce the risk of irritation.

Moisturize: After tretinoin has absorbed into your skin (usually after about 20-30 minutes), apply a non-comedogenic moisturizer to help prevent dryness and reduce irritation.

Use Sparingly: Using tretinoin more frequently or applying larger amounts than recommended will not yield better results and may increase irritation.

Be Patient: It can take several weeks to see noticeable improvements in your skin. Initial side effects like redness and peeling are common but usually subside with time. If the irritation is severe, consult your healthcare provider.

Follow Instructions: Always follow the instructions provided by your healthcare provider or on the medication label. Do not use tretinoin on broken or sunburned skin.

Avoid Harsh Products: While using tretinoin, avoid harsh skincare products that may exacerbate irritation, such as abrasive scrubs or products containing alcohol.

Regular Follow-Up: Keep in touch with your dermatologist or healthcare provider for follow-up appointments to monitor your progress and adjust your treatment plan as needed.

Don't forget to like, comment, and subscribe for more expert skincare advice from Nipun Kapur! and share this video with your friends who might find it helpful.
🌟 Connect with Nipun Kapur on social media:
Subscribe Now: https://www.youtube.com/@NipunKapur
Follow:
TIKTOK: https://www.tiktok.com/@nipunkapur
INSTAGRAM: https://www.instagram.com/NIPUNKAPUR

#How to Apply Tretinoin Cream

Demelan Cream Review: Secret to Clear Skin & Vanishing Dark Spots | Proven Results in 15 Days!”. Side Effects 3 Views • 5 months ago

#gyanitaksh #skincare #skincareroutine

Demelan Cream Review: Secret to Clear Skin & Vanishing Dark Spots | Proven Results in 15 Days!”.

Don't forget like share and subscribe
Gyani taksh
thanku you so much gyus:-
follow me:-
instagram;- http://www.instagram.com/sonu_sapna_vines
using tools
tripod :- https://amzn.eu/d/3KELWny
background:- https://amzn.eu/d/71pja19
mic:- https://amzn.eu/d/b2vmq6o
tembnial:- https://www.canva.com/design/DAFJv9x5WQU/

Your queries
Tretinoin 0.025% Cream
Tretinoin gel
Tretinoin 0.1 Cream
Tretinoin cream 0.025 uses
Tretinoin cream for acne
Tretinoin cream side effects
Tretinoin Cream Uses in Hindi
Tretinoin Cream price
Tretinoin cream 0.05 uses
Tretinoin 0.05% Cream
How to use tretinoin cream with moisturizer
Tretinoin cream
ट्रेटिन क्रीम का उपयोग कैसे करें?
Tretinoin से परिणाम देखने में कितना समय लगता है?
क्या मुझे हर रात Tretinoin 0.025 का उपयोग करना चाहिए?
Tretinoin cream ko kaise use kare
Tretinoin or glycolic acid mein sabse achi cream
Best cream for pigmentation
Best cream for dark spot
Best cream for pimples
hyperpigmentaion for best cream, tretinoin for hyperpigmentation, tretinoin cream 0.025, retinol cream for anti aging, tretinoin cream 0.025%, how to use tretinoin cream 0.025%, tretinoin cream before and after, retino a cream, starting tretinoin cream, stieva-a tretinoin cream, tretinoin cream, tretinoin cream effects, stieva-a tretinoin cream 0.05, tretinoin cream 0.1, tretinoin cream burn, how to use retin a cream, tretinoin cream journey, how to use tretinoin cream, tretinoin cream glow skin

disclaimer:- This video is not sponsored by any brand. the information provided on only knowledge purpose. Before taking any medicine consult a doctor these video is made for the purpose of your knowledge.
#gyanitaksh #beautyhacks #beautytips #beautyinfluencer #trendingbeautytips #viralbeautytricks #viralbeautytips #skinwhitening #glassskin #clearskin #clearskinsecrets #glassskinchallenge #glassskincare #darkspots #homeremedies #glowingskin #glowmask #hydratedskin #healthyglowingskin #viralshorts #musttrythisathome #trendingshorts #trendingshort #rohitsachdeva

(sonu prajapati)

IS IT OVER FOR TRETINOIN - Why Everyone Is Stopping Tretinoin Side Effects 2 Views • 5 months ago

Is it over for tretinoin and why do so many people seem to be stoping tretinoin (spoiler alert: you dont need to) how to use tretinoin for anti aging skincare.

Hey guys and welcome back to Mad About Skin where in todays video we are talking about Tretinoin and the reason why so may people online seem to be stopping tretinoin. From Kelly Driscoll through to Susan Yara and more, influencers are turning their backs on tretinoin but it doesnt mean you need to also.

Tretinoin is a high strength prescription only retinoid which has some amazing anti-ageing benefits for the skin. It has however some big side effects which you have to work your way through before you get to the tretinoin benefits at the other side. If your skin can tolerate tretinoin then using it consistently can increase the rate of cell turnover for smoother skin, fade hyperpigmentation and boost collagen to minimise fine lines and wrinkles. There are alternatives to tretinoin and so lets take a look at tretinoin in more detail.

How to use tretinoin for the best anti aging results and who maybe should avoid tretinoin in their skin care routine.

After using tretinoin (retin-a) for some time I decided to switch to retinal instead and now I use tretinoin 2 times per week for the best results and little sensitivity.

I would love to know what your experience has been with tretinoin and any other retinols so please leave me a comment below.

Products Mentioned:

Geek and Gorgeous A-Game 20
UK: https://iaff.geekandgorgeous.com/125-1-3-13.html
US: https://iaff.geekandgorgeous.com/125-38-3-45.html
Europe: https://iaff.geekandgorgeous.com/125-13-3-25.html
Other Countries: https://iaff.geekandgorgeous.com/125-1-3-13.html

Mad About Skin Ultimate Anti Aging Oil (Use Code SHIP4FREE for free shipping)
https://madaboutskincare.com/p....roducts/ultimate-ant

Timestamps:

00:00 start
02:10 end of introduction
02:15 benefits of tretinoin
04:06 why people are stopping tretinoin
05:45 alternatives to tretinoin
06:56 what cant you use with tretinoin
09:00 is tretinoin bad for your skin
10:46 summary

Wherever you are in the world, I hope you are keeping safe and well and I look forward to seeing you in the next video

xx
Rob

Shop my skincare line: https://madaboutskincare.com

For business enquiries please contact: [email protected]

#skincare #tretinoin #antiaging

Topics in this video:

skincare, skincare routine, skincare review, skin care, skin care review, skin care routine, tretinoin, how to use tetinoin, anti ageing, anti-ageing, anti aging, anti-aging, anti-ageing skincare, anti aging skincare, retin-a, retin a, how to use retin-a, how to use retin a, retinol, the best retinol, my tretinoin journey, retinol uglies, tretinoin before and after, why I stopped tretinoin, alternatives to tretinoin, mad about skin, madaboutskin, stopping tretinoin,

Tresiba® (insulin degludec) injection 100 U/mL: U-100 Overview & Coverage Side Effects 4 Views • 5 months ago

Please click here https://bit.ly/3kWYNwG, or scroll below to see Important Safety Information. Please see the Prescribing Information for Tresiba® at https://bit.ly/3JEzfPg

View information on Tresiba® FlexTouch® U-100 and learn how it compares to Insulin Glargine U-100.

For more information about features, dosing instructions, and coverage visit the Tresiba® Pro website – https://bit.ly/3XXs4pw

Indications and Usage
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications
• Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®

Warnings and Precautions
• Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
• Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.

Click here: https://bit.ly/3kWYNwG, or see video above for additional Important Safety information.

Why I Prescribe Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL For My Patients Side Effects 5 Views • 5 months ago

Please click here https://bit.ly/3kWYNwG, or scroll below to see Important Safety Information. Please see the Prescribing Information for Tresiba® at https://bit.ly/3JEzfPg

Philip Woodham, MD, discusses why he prescribes Tresiba® as a long-acting insulin for his appropriate patients with diabetes.

Hear from health care professionals about Tresiba® on the Tresiba® Pro website – https://bit.ly/3RrBiYM

Indications and Usage
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications
• Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®

Warnings and Precautions
• Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
• Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.

Click here: https://bit.ly/3kWYNwG, or see video above for additional Important Safety information.

How Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL Works With Dr Gavin Side Effects 3 Views • 5 months ago

Please click here https://bit.ly/3kWYNwG, or scroll below to see Important Safety Information. Please see the Prescribing Information for Tresiba® at https://bit.ly/3JEzfPg

Renowned diabetes expert Dr James R Gavin, III and past president of Morehouse College School of Medicine examines the mechanism of protraction of Tresiba®.

For more information on how Tresiba® works visit the Tresiba® Pro website – https://bit.ly/3Yhk7vL

Indications and Usage
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications
• Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®

Warnings and Precautions
• Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
• Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.

Click here: https://bit.ly/3kWYNwG, or see video above for additional Important Safety information.

Tresiba® FlexTouch® (insulin degludec) injection 100 U/mL: How to Use Side Effects 4 Views • 5 months ago

Learn how to use the Tresiba® FlexTouch® (insulin degludec) injection U-100 pen. See Important Safety Information below.

Please click here to see the Prescribing Information for Tresiba® — https://www.novo-pi.com/tresiba.pdf.

What is Tresiba®?
• Prescription Tresiba® is a long-acting insulin used to control high blood sugar in adults and children who are 1 year of age and older with diabetes
• Tresiba® is not for people with diabetic ketoacidosis (increased ketones in the blood or urine)
• It is not known if Tresiba® is safe and effective in children under 1 year of age
• Tresiba® is available in 2 concentrations: 200 units/mL and 100 units/mL

Important Safety Information
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.

Who should not take Tresiba®?
Do not take Tresiba® if you:
• are having an episode of low blood sugar
• have an allergy to Tresiba® or any of the ingredients in Tresiba®

Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:
• pregnant, planning to become pregnant, or are breastfeeding
• taking new prescription or over-the-counter medicines, vitamins, or herbal supplements

Talk to your health care provider about low blood sugar and how to manage it.

How should I take Tresiba®?
• Read the Instructions for Use and take Tresiba® exactly as your health care provider tells you to
• Do not do any conversion of your dose. The dose counter always shows the selected dose in units
• Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to
• Adults - If you miss or are delayed in taking your dose of Tresiba®:
o Take your dose as soon as you remember, then continue with your regular dosing schedule
o Make sure there are at least 8 hours between doses
• If children miss a dose of Tresiba®:
o Call the healthcare provider for information and instructions about checking blood sugar levels more often until the next scheduled dose of Tresiba®
• For children who need less than 5 units of Tresiba® each day, use a Tresiba® U-100 vial
• Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them
• Do not reuse or share your needles or syringes with other people. You may give them a serious infection, or get a serious infection from them
• Never inject Tresiba® into a vein or muscle
• Never use a syringe to remove Tresiba® from the FlexTouch® pen
• Tresiba® can be injected under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen).
• Change (rotate) your injection sites within the area you choose with each injection to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
o Do not use the exact same spot for each injection.
o Do not inject where the skin has pits, is thickened, or has lumps.
o Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.

What should I avoid while taking Tresiba®?
• Do not drive or operate heavy machinery, until you know how Tresiba® affects you
• Do not drink alcohol or use prescription or over-the-counter medicines that contain alcohol

What are the possible side effects of Tresiba®?
Tresiba® may cause serious side effects that can be life-threatening, including:
• Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include dizziness, light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heart beat, anxiety, irritability, mood changes, and hunger.
• Low potassium in your blood (hypokalemia)
• Heart failure in some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Tresiba®. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain

Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.

Common side effects may include serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain.

Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.

A Physician's Take On Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL FlexTouch® Side Effects 5 Views • 5 months ago

Please click here https://bit.ly/3kWYNwG, or scroll below to see Important Safety Information. Please see the Prescribing Information for Tresiba® at https://bit.ly/3JEzfPg

Steven Edelman, MD, reviews the features of Tresiba® FlexTouch® U-100 and U-200 and how device options play a role in his prescribing decisions.

For more information about Tresiba® FlexTouch® and vial visit the Tresiba® Pro website – https://bit.ly/3XXs4pw

Indications and Usage
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications
• Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®

Warnings and Precautions
• Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
• Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.

Click here: https://bit.ly/3kWYNwG, or see video above for additional Important Safety information.

Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL Duration of Action With Dr Gavin Side Effects 2 Views • 5 months ago

Please click here https://bit.ly/3kWYNwG, or scroll below to see Important Safety Information. Please see the Prescribing Information for Tresiba® at https://bit.ly/3JEzfPg

Hear about the pharmacokinetics behind the duration of action of Tresiba® from past president of Morehouse College School of Medicine and renowned diabetes expert Dr James R Gavin, III.

For more information about the duration of action of Tresiba® visit the Tresiba® Pro website – https://bit.ly/3RyvOeH

Indications and Usage
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications
• Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®

Warnings and Precautions
• Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
• Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.

Click here: https://bit.ly/3kWYNwG, or see video above for additional Important Safety information.

Instructions For Using Tresiba® FlexTouch® U-100 (insulin degludec) injection Side Effects 3 Views • 5 months ago

Please click here https://bit.ly/3kWYNwG, or scroll below to see Important Safety Information. Please see the Prescribing Information for Tresiba® at https://bit.ly/3JEzfPg

Help your patients learn to use the Tresiba® U-100 Pen in this easy to follow video which shows detailed instructions on how to administer Tresiba® insulin.

For more information on Tresiba®, including cost and coverage, and resources for you and your patients, visit the Tresiba® Pro website – https://bit.ly/3XXs4pw

Indications and Usage
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications
• Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®

Warnings and Precautions
• Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
• Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.

Click here: https://bit.ly/3kWYNwG, or see video above for additional Important Safety information.